Rather than going to trial Monday, Teva Pharmaceutical Industries Ltd. agreed to pay at least $1.2 billion to settle a 2008 FTC lawsuit challenging pay-for-delay agreements Cephalon Inc. used to fend off generic competition to its blockbuster sleep-disorder drug Provigil.
What do the Boston Marathon bombing and the Ebola epidemic have in common? The lessons learned in responding to the attack and the viral epidemic will help advance medical countermeasures (MCMs) and future emergency responses.
While it's not a death knell for the life cycle approach of building a drug franchise, an appellate court ruling in People of the State of New York v. Actavis plc could kill one tactic a few drugmakers have used to protect a blockbuster franchise from generic competition: forced switching to the next-generation product.
In a self-declared "love fest," the House Energy and Commerce Committee put aside partisan politics Thursday, voting 51-0 to pass the 21st Century Cures Act, H.R. 6, in the hope of streamlining the process of developing and approving new medical treatments.
Defending patents for drugs and medical devices is part of the stakes of an R&D budget, but the size of that stake could increase significantly if a hedge fund manager wins his inter partes review (IPR) challenge of selected drug patents.
As the race heats up to translate promising human gene-editing technologies from the academic lab to human trials, U.S. policy advisers are trying to catch up with the research to answer questions about potential risks and ethical concerns.
The success of its breakthrough hepatitis C drug Sovaldi could come back to slap Gilead Sciences Inc., as government agencies like the Department of Veterans Affairs (VA) struggle to pay for the growing demand for the drug.
